Evidence map›Paper›PMID 21636851›Full record

ArticleThe Journal of biological chemistry2011

Epigenetic regulation of phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 gene expression in prostate cancer cells.

Chuu-Yun A Wong, Hada Wuriyanghan, Yan Xie, Ming-Fong Lin, Peter W Abel, Yaping Tu

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Effects of Arf6 downregulation on biological characteristics of human prostate cancer cells.International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chuu-Yun A WongDepartment of Pharmacology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.
Hada Wuriyanghan
Yan Xie
Ming-Fong Lin
Peter W Abel
Yaping Tu
Creighton University · USUniversity of Nebraska Medical Center · US

Funding

SIGNALING IN ANDROGEN REFRACTORY PROSTATE CANCERR01CA088184 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LIN, MING-FONG · 2000 to 2010
$2.6M
Regulator of G-protein Signaling (RGS) Proteins in Prostate CancerR01CA125661 · NCI · CREIGHTON UNIVERSITY · PI TU, YAPING · 2007 to 2011
$1.2M
NCI NIH HHS CA125661NCI NIH HHS CA88184NCI NIH HHS R01 CA088184NCI NIH HHS R01 CA125661
6 · The paper itself

Abstract

Aberrant up-regulation of P-Rex1 expression plays important roles in cancer progression and metastasis. The present study investigated the regulatory mechanism underlying P-Rex1 gene expression in prostate cancer cells. We showed that P-Rex1 expression was much higher in metastatic prostate cancer cells than in prostate epithelial cells and non-metastatic prostate cancer cells. Histone deacetylase (HDAC) inhibitors or silence of endogenous HDAC1 and HDAC2 markedly elevated P-Rex1 transcription in non-metastatic prostate cancer cells, whereas overexpression of recombinant HDAC1 in metastatic prostate cancer cells suppressed P-Rex1 expression. HDAC inhibitor trichostatin A (TSA) also significantly increased P-Rex1 promoter activity and caused acetylated histones to accumulate and associate with the P-Rex1 promoter. One Sp1 site, essential for basal promoter activity, was identified as critical for the TSA effect. TSA treatment did not alter the DNA-binding activity of Sp1 toward the P-Rex1 promoter; however, it facilitated the dissociation of the repressive HDAC1 and HDAC2 from the Sp1 binding region. Interestingly, HDAC1 association with Sp1 and with the P-Rex1 promoter were much weaker in metastatic prostate cancer PC-3 cells than in non-metastatic prostate cancer cells, and HDAC inhibitors only had very modest stimulatory effects on P-Rex1 promoter activity and P-Rex1 expression in PC-3 cells. Altogether, our studies demonstrate that HDACs could regulate P-Rex1 gene transcription by interaction with Sp1 and by region-specific changes in histone acetylation within the P-Rex1 promoter. Disassociation of HDACs from Sp1 on the P-Rex1 promoter may contribute to aberrant up-regulation of P-Rex1 in cancer.

Indexed as

Epigenesis, GeneticAnimalsBase SequenceBinding SitesCell Line, TumorEpithelial CellsGene Expression Regulation, NeoplasticGuanine Nucleotide Exchange FactorsHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase InhibitorsHumansHydroxamic AcidsMaleNeoplasm MetastasisPromoter Regions, GeneticGuanine Nucleotide Exchange FactorsHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase InhibitorsHydroxamic AcidsPREX1 protein, humanSp1 Transcription Factortrichostatin A

Identifiers

PMID21636851
PMCPMC3138273
OpenAlexW2088512658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.